Skip to main content

Table 3 Treatment cohorts and most common treatment patterns within each cohort

From: Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis

 

N (%)a

Total Number of Patients – Analysis Sub-Sample

21,088 (100%)

Number of patients with 3 most common treatment patterns within each cohort

14,882 (70.6%)

Discontinuation (Cohort 1)

10,358 (49.1)

 Pattern 1a: Discontinuation → Remained Untreated

4833 (22.9)

 Pattern 1b: Discontinuation → Resumption → Discontinuation → Resumption

2364 (11.2)

 Pattern 1c: Discontinuation → Resumption → Discontinuation → Remained Untreated

1158 (5.5)

 other patterns

2003 (9.5)

Dose Escalation (Cohort 2)

7879 (37.4)

 Pattern 2a: Escalation → Discontinuation → Remained Untreated

1918 (9.1)

 Pattern 2b: Escalation → Discontinuation → Resumption → Discontinuation

1866 (8.8)

 Pattern 2c: Escalation → Persistence

1104 (5.2)

 other patterns

2991 (14.2)

Switch (Cohort 3)

1390 (6.6)

 Pattern 3a: Switch → Discontinuation → Remained Untreated

275 (1.3)

 Pattern 3b: Switch → Discontinuation → Resumption → Discontinuation

198 (0.9)

 Pattern 3c: Switch → Escalation → Discontinuation → Resumption

185 (0.9)

 other patterns

732 (3.5)

Persistence (Cohort 4)

732 (3.5)b,c

 Combination (Cohort 5)

588 (2.8)c

  Pattern 5a: Combination → Switch/Drop → Discontinuation → Resumption

82 (0.4)

  Pattern 5b: Combination → Escalation → Switch/Drop → Combination

58 (0.3)

  Pattern 5c: Combination → Switch/Drop → Combination → Switch/Drop

60 (0.3)

  other patterns

388 (1.8)

Augmentation (Cohort 6)

141 (0.7)c

 Pattern 6a: Augmentation → Switch/Drop → Augmentation → Switch/Drop

19 (0.1)

 Pattern 6b: Augmentation → Switch/Drop → Discontinuation → Resumption

18 (0.1)

 Pattern 6c: Augmentation → Persistence

12 (0.1)

 other patterns

83 (0.4)

  1. aAll percentages were computed among the total number of patients in the analysis sub-sample (N = 21,088)
  2. bThe mean and median duration of treatment for the persistence cohort was 37.9 and 33.6 months, respectively
  3. cTreatment cohorts representing <5% of the analysis sub-sample were not further analyzed due to limited sample size (decided a priori)
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us